Synthesis and testing of peptides for anti-prion activity

Shane Sellarajah, Cyrille Boussard, Tarnuna Lekishvili, David R. Brown, Ian H. Gilbert

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Creutzfeldt-Jakob disease (CJD) is one of the fatal transmissible spongiform encephalopathies for which there is no known cure. The disease is associated with an abnormally folded prion protein, PrP-res, which is thought to form due to interaction between normal prion PrPC and PrP-es. Small peptides were designed to prevent this interaction. A structure-activity relationship is described for a series of peptides which were synthesised and tested for their activity against two prion disease model assays, an in vitro cellular assay and an in vitro anti-aggregation polymerisation assay. A number of peptides were found to be active at levels of 100 mu M. New libraries were synthesised in order to concentrate on discovering new, shorter peptides which could be leads for developing peptidomimetics. (C) 2008 Elsevier Masson SAS. All rights reserved.

    Original languageEnglish
    Pages (from-to)2418-2427
    Number of pages10
    JournalEuropean Journal of Medicinal Chemistry
    Volume43
    Issue number11
    DOIs
    Publication statusPublished - Nov 2008

    Keywords

    • Prion
    • Transmissible spongiform encephalopathy
    • Peptide
    • TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES
    • CONGO RED
    • HIV PROTEINASE
    • INHIBITION
    • DISEASES
    • THERAPEUTICS
    • PRP
    • CONSEQUENCES
    • HAMSTERS
    • BINDING

    Cite this

    Sellarajah, Shane ; Boussard, Cyrille ; Lekishvili, Tarnuna ; Brown, David R. ; Gilbert, Ian H. / Synthesis and testing of peptides for anti-prion activity. In: European Journal of Medicinal Chemistry. 2008 ; Vol. 43, No. 11. pp. 2418-2427.
    @article{4fa1ec54f55c4ba3a19620516510b60f,
    title = "Synthesis and testing of peptides for anti-prion activity",
    abstract = "Creutzfeldt-Jakob disease (CJD) is one of the fatal transmissible spongiform encephalopathies for which there is no known cure. The disease is associated with an abnormally folded prion protein, PrP-res, which is thought to form due to interaction between normal prion PrPC and PrP-es. Small peptides were designed to prevent this interaction. A structure-activity relationship is described for a series of peptides which were synthesised and tested for their activity against two prion disease model assays, an in vitro cellular assay and an in vitro anti-aggregation polymerisation assay. A number of peptides were found to be active at levels of 100 mu M. New libraries were synthesised in order to concentrate on discovering new, shorter peptides which could be leads for developing peptidomimetics. (C) 2008 Elsevier Masson SAS. All rights reserved.",
    keywords = "Prion, Transmissible spongiform encephalopathy, Peptide, TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES, CONGO RED, HIV PROTEINASE, INHIBITION, DISEASES, THERAPEUTICS, PRP, CONSEQUENCES, HAMSTERS, BINDING",
    author = "Shane Sellarajah and Cyrille Boussard and Tarnuna Lekishvili and Brown, {David R.} and Gilbert, {Ian H.}",
    year = "2008",
    month = "11",
    doi = "10.1016/j.ejmech.2008.01.041",
    language = "English",
    volume = "43",
    pages = "2418--2427",
    journal = "European Journal of Medicinal Chemistry",
    issn = "0223-5234",
    publisher = "Elsevier",
    number = "11",

    }

    Synthesis and testing of peptides for anti-prion activity. / Sellarajah, Shane; Boussard, Cyrille; Lekishvili, Tarnuna; Brown, David R.; Gilbert, Ian H.

    In: European Journal of Medicinal Chemistry, Vol. 43, No. 11, 11.2008, p. 2418-2427.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Synthesis and testing of peptides for anti-prion activity

    AU - Sellarajah, Shane

    AU - Boussard, Cyrille

    AU - Lekishvili, Tarnuna

    AU - Brown, David R.

    AU - Gilbert, Ian H.

    PY - 2008/11

    Y1 - 2008/11

    N2 - Creutzfeldt-Jakob disease (CJD) is one of the fatal transmissible spongiform encephalopathies for which there is no known cure. The disease is associated with an abnormally folded prion protein, PrP-res, which is thought to form due to interaction between normal prion PrPC and PrP-es. Small peptides were designed to prevent this interaction. A structure-activity relationship is described for a series of peptides which were synthesised and tested for their activity against two prion disease model assays, an in vitro cellular assay and an in vitro anti-aggregation polymerisation assay. A number of peptides were found to be active at levels of 100 mu M. New libraries were synthesised in order to concentrate on discovering new, shorter peptides which could be leads for developing peptidomimetics. (C) 2008 Elsevier Masson SAS. All rights reserved.

    AB - Creutzfeldt-Jakob disease (CJD) is one of the fatal transmissible spongiform encephalopathies for which there is no known cure. The disease is associated with an abnormally folded prion protein, PrP-res, which is thought to form due to interaction between normal prion PrPC and PrP-es. Small peptides were designed to prevent this interaction. A structure-activity relationship is described for a series of peptides which were synthesised and tested for their activity against two prion disease model assays, an in vitro cellular assay and an in vitro anti-aggregation polymerisation assay. A number of peptides were found to be active at levels of 100 mu M. New libraries were synthesised in order to concentrate on discovering new, shorter peptides which could be leads for developing peptidomimetics. (C) 2008 Elsevier Masson SAS. All rights reserved.

    KW - Prion

    KW - Transmissible spongiform encephalopathy

    KW - Peptide

    KW - TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

    KW - CONGO RED

    KW - HIV PROTEINASE

    KW - INHIBITION

    KW - DISEASES

    KW - THERAPEUTICS

    KW - PRP

    KW - CONSEQUENCES

    KW - HAMSTERS

    KW - BINDING

    U2 - 10.1016/j.ejmech.2008.01.041

    DO - 10.1016/j.ejmech.2008.01.041

    M3 - Article

    C2 - 18355947

    VL - 43

    SP - 2418

    EP - 2427

    JO - European Journal of Medicinal Chemistry

    JF - European Journal of Medicinal Chemistry

    SN - 0223-5234

    IS - 11

    ER -